Zobrazeno 1 - 8
of 8
pro vyhledávání: '"F. Joel Leong"'
Publikováno v:
Malaria Journal, Vol 17, Iss 1, Pp 1-11 (2018)
Abstract Background KAF156 is a novel imidazolopiperazine anti-malarial with activity against pre-erythrocytic liver stages, asexual and sexual blood stages. Based on in vitro data, a two-way pharmacokinetic interaction was hypothesized for KAF156 us
Externí odkaz:
https://doaj.org/article/85c32f821eb644bd81783a0789e93e01
Publikováno v:
ACS Infectious Diseases. 2:530-537
The apicomplexan parasite Cryptosporidium is the second most important diarrheal pathogen causing life-threatening diarrhea in children, which is also associated with long-term growth faltering and cognitive deficiency. Cryptosporidiosis is a parasit
Autor:
Lan Chen, Jagannath Kota, Vishal Koradia, Gangadhar Sunkara, Marie-Christine Wolf, Sampath Kalluri, F. Joel Leong, Daniel S. Stein, Jay Prakash Jain
Publikováno v:
Antimicrobial Agents and Chemotherapy
The artemether-lumefantrine combination requires food intake for the optimal absorption of lumefantrine. In an attempt to enhance the bioavailability of lumefantrine, new solid dispersion formulations (SDF) were developed, and the pharmacokinetics of
Autor:
Thierry T. Diagana, Suresh B. Lakshminarayana, Susan Noh, Francesca Blasco, Carrie F. Brooks, Jennifer A. Zambriski, Laura B. Goodman, Gu Feng, Sumiti Vinayak, Gillian T. Herbert, Peter Gedeck, Lijun Zhang, Jayesh Tandel, Siau H. Lim, Christian G. Noble, F. Joel Leong, Alex Chao, Juergen Wagner, Bin Zou, Boris Striepen, Tracy Sy, Ravinder Reddy Kondreddi, Christophe Bodenreider, Ujjini H. Manjunatha, Ghislain M. C. Bonamy, Adam Sateriale
Publikováno v:
Nature
Diarrhoeal disease is responsible for 8.6% of global child mortality. Recent epidemiological studies found the protozoan parasite Cryptosporidium to be a leading cause of paediatric diarrhoea, with particularly grave impact on infants and immunocompr
Autor:
Kittiphum Chuthasmit, Ming S. Cheung, François Nosten, Nicholas J. White, F. Joel Leong, Daniela Wieser, Baldur Magnusson, Peter Pertel, Tran T. Duong, Thierry T. Diagana, Aung Pyae Phyo, Rong Zhao, Marc Sultan, Chirapong Uthaisin, Yiyan Feng, Borimas Hanboonkunupakarn, Sasithon Pukrittayakamee, Podjanee Jittamala, Ruobing Li, Xiaolei Xun
KAF156 belongs to a new class of antimalarial agents (imidazolopiperazines), with activity against asexual and sexual blood stages and the preerythrocytic liver stages of malarial parasites.We conducted a phase 2, open-label, two-part study at five c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::530cf19aa6ba4d8c13d934418725a18f
https://doi.org/10.1056/nejmoa1602250
https://doi.org/10.1056/nejmoa1602250
Publikováno v:
Antimicrobial Agents and Chemotherapy
KAF156 belongs to a new class of antimalarial, the imidazolopiperazines, and is currently in clinical development for the treatment of uncomplicated malaria. This first-in-human, single- and multiple-ascending-dose study in 70 healthy male volunteers
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.